13-04-2016 12:00-13:00 Industry Satellite Symposium 1 (TBC) Room A 13:30-13:45 Opening and Welcome Room B Chair: W. Eberhardt, DE; S. Peters, CH 13:45-14:15 Heine H. Hansen Award Lecture Room B 14:30-16:00 SCLC: Advances and state of the art Room B 14:30-14:45 Staging update on SCLC A. Nicholson, UK 14:45-15:05 Genetics and genetic targets in SCLC J. Poirier, NY/US 15:05-15:20 Translational studies in SCLC M. Edelman, MD/US 15:20-15:35 Advances in systemic treatment of SCLC excluding immunotherapy K. Kubota, JP 15:35-15:50 Radiation therapy in SCLC B. Slotman, NL 15:50-16:00 Questions and Answers
14:30-16:00 Mesothelioma: An update Room A 14:30-14:50 New markers in distinguishing reactive from neoplastic mesothelial proliferations S. Lantuejoul, FR 14:50-15:10 Surgical options for patients with mesothelioma in 2016 W. Weder, CH 15:10-15:30 Non-surgical treatment options for mesothelioma P. Baas, NL 15:30-15:50 Genetic profiling and the impact of future therapy of mesotheliomas D. Fennell, UK 15:50-16:00 Questions and Answers 16:00-16:30 Coffee break Hall 1 16:30-18:00 Targeting T790M Room B 16:30-16:50 Advancing technology on blood-based testing for detection of T790M J. Wang, CN 16:50-17:10 A new era of T790M inhibition T.S.K. Mok, CN 17:10-17:30 Mechanism of resistance to T790M inhibitors S. Ramalingam, GA/US 17:30-17:50 T790M inhibitor as first line therapy: Promises and pitfalls J.-C. Soria, FR 17:50-18:00 Questions and Answers
16:30-18:00 Oligometastatic NSCLC Room A 16:30-16:50 Overview: Incidence and literature on surgical and ablative approaches F. Mornex, FR 16:50-17:10 Oligometastatic NSCLC with driver mutations: Guidelines and practical application L. Shun, CN 17:10-17:30 Oligometastatic NSCLC without driver mutations: New developments, including immunotherapy E. Smit, NL 17:30-17:50 Surgery in oligometastatic disease Y.L. Wu, CN 17:50-18:00 Questions and Answers 18:30-20:00 Industry Satellite Symposium 2 (TBC) Room A 14-04-2016 08:00-08:50 Optimizing the use of TKI in oncogene addicted NSCLC Room A 08:00-08:15 Treatment of EGFR mutation patients K. O'Byrne, AU 08:15-08:30 Treatment of ALK positive tumours B. Solomon, AU 08:30-08:50 Discussion 08:00-08:50 Young Oncologists session (Title TBC) Room X
08:00-08:50 Stereotactic radiotherapy for metastatic NSCLC Room W 08:00-08:15 Checkpoint inhibition: a perspective and a glimpse into the future L. Gaspar, CO/US 08:15-08:30 SBRT in the oligo-metastatic setting: Multiple targets and combination with systemic treatment J. Widder, NL 08:30-08:50 Discussion 09:00-10:30 Targeting ALK Room B 09:00-09:20 Science overview, mechanisms of resistance C. Lovly, TN/US 09:20-09:40 Practical management of ALK mutation patients S. Novello, IT 09:40-10:00 Clinical trials with novel agents B. Solomon, AU 10:00-10:20 Sequencing of agents M. Perol, FR 10:20-10:30 Questions and Answers 09:00-10:30 Smoking prevention and cessation Room C 09:00-09:25 How to move forward from LDCT screening J. Field, UK 09:25-09:55 Cancer prevention: From challenges in smoking cessation to the implementation of screening programmes J.L. Mulshine, IL/US 09:55-10:20 Cost-effectiveness of the prevention of lung cancer W. Evans, CA 10:20-10:30 Questions and Answers
10:30-11:00 Coffee break Hall 1 11:00-12:30 The difficult targets: KRAS, PIK3CA and FRGF1/2 Room B 11:00-11:20 KRAS G. Giaccone, MD/US 11:20-11:40 PIK3CA M. Schuler, DE 11:40-12:00 FRGF1/2 R. Camidge, CO/US 12:00-12:20 Future perspective on managing resistance mechanisms G. Giaccone, MD/US 12:20-12:30 Questions and Answers / Panel Discussion 11:00-12:30 Molecular characterisation of NSCLC: What should we really get for our patients? Room A 11:00-11:20 Targetable genome alterations in squamous cell lung cancer K. Park, KR 11:20-11:40 Tracking lung cancer genome evolution under targeted therapy I. Wistuba, TX/US 11:40-12:00 Novel insights into genome alterations of small cell lung cancer J. George, DE 12:00-12:20 Targeting developmental pathways in small cell lung cancer A.A. Adjei, NY/US 12:20-12:30 Questions and Answers / Panel Discussion
11:00-12:30 Radiation Oncology NSCLC: Current developments and state-of-the-art Room C 11:00-11:20 SBRT for stage I S. Senan, NL 11:20-11:40 Stage IIIA: Trimodal versus radiochemotherapy M. Stuschke, DE 11:40-12:00 Stage IIIB: Primary radiochemotherapy R. Dziadziuszko, PL 12:00-12:20 Radiation therapy for oligometastatic disease M. Guckenberger, CH 12:20-12:30 Questions and Answers / Panel Discussion 11:00-12:30 Sublobar resections: When and how Room X 11:00-11:20 The current value of wedge resections D. Wood, WA/US 11:20-11:40 Technical aspects of sublobar resection and oncological indications H. Asamura, JP 11:40-12:00 Length of stay and postoperative morbidity D. Gossot, FR 12:00-12:20 Quality of sub lobar resections D. Waller, UK 12:20-12:30 Questions and Answers / Panel Discussion
11:00-12:30 New frontiers in endoscopy Room W 11:00-11:20 Bronchoscopy in the era of early and screen detected peripheral nodules C. Dooms, BE 11:20-11:40 In vivo cellular imaging of lung cancer L. Thiberville, FR 11:40-12:00 Endobronchial treatment and follow up of malignant central airway obstruction K. Darwiche, DE 12:00-12:20 Diagnostic and therapeutic approach(es) to malignant pleural effusion N. Peled, IL 12:20-12:30 Questions and Answers / Panel Discussion 12:30-13:00 Poster lunch Hall 1 13:00-14:00 Industry Satellite Symposium 3 (TBC) Room A 14:10-14:40 Basic immunotherapy for current and future cancer treatment strategies Room B 14:10-14:40 Basic immunotherapy for current and future cancer treatment strategies J. Haanen, NL 14:45-16:15 Proffered Papers 1 Room B
14:45-16:15 Radiotherapeutic issues of dose and fractionation Room A 14:45-15:05 Current state-of-the-art and future directions of time/dose/fractionation for radio(chemo)therapy of lung cancer J. Belderbos, NL 15:05-15:25 Optimizing the therapeutic ratio using novel radiotherapy technology D. De Ruysscher, BE 15:25-15:45 Peripheral, central and too-central: Tumour location and practice of SBRT in early stage NSCLC U. Nestle, DE 15:45-16:05 Efficacy of SBRT: Just an issue of dose or different radiobiology? N. Andratschke, CH 16:05-16:15 Questions and Answers 14:45-16:00 Poster Discussion 1 Room W 16:15-16:45 Coffee break Hall 1 16:45-18:00 Poster Discussion 2 Room W 18:40-19:40 Industry Satellite Symposium 4 (TBC) Room A 18:40-19:40 Industry Satellite Symposium 5 (TBC) Room C 15-04-2016 08:00-08:50 Combining TKI with other strategies Room A 08:00-08:15 Targeted agents and radiotherapy in locally advanced disease F. Mornex, FR 08:15-08:30 The role of local therapies in advanced molecular-driven NSCLC J. Vansteenkiste, BE 08:30-08:50 Discussion 08:00-08:50 Young Oncologists 2 Room X
08:00-08:50 PCI in SCLC and NSCLC Room W 08:00-08:15 Current controversies in SCLC T. Seto, JP 08:15-08:30 Any role in NSCLC C. Le Péchoux, FR 08:30-08:50 Discussion 09:00-10:30 Immunotherapy Room B 09:00-09:20 Immunotherapy as a new standard of care in NSCLC M. Reck, DE 09:20-09:40 Immunotherapy in thoracic malignancies beyond NSCLC S. Peters, CH 09:40-10:00 Clinical trial designs and ongoing trials in thoracic immune-oncology D. Carbone, OH/US 10:00-10:20 The quest for an immunotherapy biomarker K. Kerr, UK 10:20-10:30 Questions and Answers 09:00-10:30 Proffered Papers 3 Room C 10:30-11:00 Coffee break Hall 1
11:00-12:30 How to improve stage III NSCLC multimodality treatment Room B 11:00-11:20 Recent developments in the landscape of stage III K.S. Albain, IL/US 11:20-11:40 Radiotherapy innovations relevant for stage III M. Stuschke, DE 11:40-12:00 Surgical techniques relevant for stage III G. Stamatis, DE 12:00-12:20 Systemic treatment with future impact on stage III S. Peters, CH 12:20-12:30 Questions and Answers 11:00-12:30 New molecular targets of interest Room A 11:00-11:20 B-RAF D. Planchard, FR 11:20-11:40 RET J. Wolf, DE 11:40-12:00 FGFR1 R. Camidge, CO/US 12:00-12:20 HER2 E. Felip, ES 12:20-12:30 Questions and Answers
11:00-12:30 Thymic malignancy: An update Room C 11:00-11:20 Signal conduction pathways in thymic malignancies Y. Ohe, JP 11:20-11:40 Systemic approaches to thymic malignancies: State of the art N. Girard, FR 11:40-12:00 Surgical management of thymic malignancies E. Ruffini, IT 12:00-12:20 Pathology diagnoses in thymic malignancies A. Marx, DE 12:20-12:30 Questions and Answers 12:30-13:00 Poster lunch Hall 1 13:00-14:00 Industry Satellite Symposium 6 (TBC) Room A 13:00-14:00 Industry Satellite Symposium 7 (TBC) Room C 14:10-14:40 (History of) Platinum in lung cancer Room B 14:10-14:40 (History of) Platinum in lung cancer L.H. Einhorn, IN/US 14:45-16:00 Poster Discussion 3 Room W 16:15-16:45 Coffee break Hall 1 16:45-18:15 ESMO-IASLC Best Abstracts Room B
16:45-18:15 Collaborative efforts for rare molecularly defined NSCLC Room A 16:45-17:05 Building TCGA and alchemist networks R. Govindan, MO/US 17:05-17:25 The SPECTAlung program B. Besse, FR 17:25-17:45 The Lungscape program R.A. Stahel, CH 17:45-18:05 The SAFIR umbrella trial F. Barlesi, FR 18:05-18:15 Questions and Answers 16:45-18:15 Special session (TBC) Room W 18:40-19:40 Industry Satellite Symposium 8 (TBC) Room A 18:40-19:40 Industry Satellite Symposium 9 (TBC) Room C 16-04-2016 08:45-09:15 Lung cancer care: The last and the next 5 years perspectives Room A 08:45-09:15 Lung cancer care: The last and the next 5 years perspectives J.-C. Soria, FR
09:20-10:50 WHO 2015 Room A 09:20-09:40 Impact of the new classification: The pathologist s view K. Kerr, UK 09:40-10:00 Impact of the new classification: The surgeon s view P. Van Schil, BE 10:00-10:20 Neuroendocrine tumours: Update and controversies W. Travis, NY/US 10:20-10:40 WHO2015: Small sample diagnosis in lung cancer E. Brambilla, FR 10:40-10:50 Questions and Answers 10:50-11:20 Coffee break Hall 1 11:20-12:50 Minimally invasive local approaches Room A 11:20-11:40 Measures to improve outcomes after surgery J. Kuzdzal, PL 11:40-12:00 Organ sparing surgery: Sublobar anatomical resection versus lobectomy? S. Welter, DE 12:00-12:20 Evaluating surgery versus SABR in clinical trials: New insights K. Franks, UK 12:20-12:40 A patients perspective on outcomes D. Timmermans, NL 12:40-12:50 Questions and Answers 12:50-13:00 Closing remarks Room A Chair: W. Eberhardt, DE; S. Peters, CH